Head-to-head dispatch
Coivas vs Peter MD
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Coivas is an all-inclusive GLP-1 telehealth service operated by WellVi LLC (d/b/a Coivas) with prescriptions through Arora Health & Aesthetics, LLC.
Marked down on: Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
Desk Score
A physician-prescribed telehealth brand pairing GLP-1 tirzepatide and compounded semaglutide+B12 with TRT, sermorelin, NAD+, hair-loss and ED care on one account — tirzepatide from $249/mo, semaglutide+B12 from $149/mo.
Marked down on: Tirzepatide steps up after month one — $149 for the first month, then $249/mo billed quarterly
Peter MD takes this head-to-head with the higher Desk Score, 80/100 (B−) against 65/100 (C) for Coivas. Coivas still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Coivas
65/100
C
Peter MD
80/100
B−
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Coivas | Peter MD |
|---|---|---|
| Semaglutide | $149/mo (quarterly plan, compounded) | $149/mo (GLP1+B12, compounded, first-time tier; $139/mo returning-patient tier) |
| Tirzepatide | $229/mo (quarterly plan, compounded) | $249/mo (60mg, billed quarterly; $149 first month) |
| Coverage | Coverage not published | Most states (restrictions vary by treatment — excludes several, incl. AL, ID) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Readers who want all-inclusive compounded GLP-1 pricing with a money-back guarantee. | Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes. |
| Desk Score | 65/100C | 80/100B− |
The verdict
Desk pick — Peter MDPeter MD takes this head-to-head with the higher Desk Score, 80/100 (B−) against 65/100 (C) for Coivas. Coivas still holds its ground where its strengths line up with yours.
Choose Coivas if…
Readers who want all-inclusive compounded GLP-1 pricing with a money-back guarantee.
$149/mo (quarterly plan, compounded) sema · $229/mo (quarterly plan, compounded) tirz · Coverage not published
Choose Peter MD if…
Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes.
$149/mo (GLP1+B12, compounded, first-time tier; $139/mo returning-patient tier) sema · $249/mo (60mg, billed quarterly; $149 first month) tirz · Most states (restrictions vary by treatment — excludes several, incl. AL, ID)
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Coivas · Peter MD.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Coivas vs CoreAge Rx
- Peter MD vs Vaylen
- Coivas vs Strut Health
- Peter MD vs Ondra Health
- Coivas vs Invigor Medical
- Peter MD vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.